Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma

Cancer

Volumn 92, Issue 2, 2001, Pages 386-394

  Natsume, Tsugitaka ^a   Kobayashi, Motohiro ^a   Fujimoto, Shuichi ^b  

^a Grelan Pharmaceutical Co Ltd   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

Nonsmall cell lung carcinoma; p53 status; Renal cell carcinoma; Sensitivity; TZT 1027

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; AURISTATIN PE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; PROTEIN P53; VINDESINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; DRUG STRUCTURE; EXON; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; DNA DAMAGE; FEMALE; GENES, P53; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0035878964     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010715)92:2<386::AID-CNCR1334>3.0.CO;2-V     Document Type: Article

References (39)

1. p53, guardian of the genome
2. Participation of p53 protein in the cellular response to DNA damage
3. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
4. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
5. p53 status and the efficacy of cancer therapy in vivo
6. Synthesis and antitumor activity of novel dolastatin 10 analogs
7. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative
8. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin
9. Inactivation of the retinoblastorna susceptibility gene in non-small-cell lung cancer
10. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma
11. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung
12. Association of point mutation in c-Ki-ras oncogene in lung adenocarcinoma with particular reference to cytologic subtypes
13. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung
14. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
15. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas
16. Mutations of the p53 gene in human astrocytic tumors correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anticancer agents
17. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry
18. Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay
19. Phase I clinical and pharmacokinetic study of taxol
20. Phase I clinical study of CPT-11
21. Experimental evaluation of potential anticancer agents. XIX. Sensitivity of nondividing leukemic cell populations to certain classes of drugs in vivo
22. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man
23. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals
24. Detection of aberration of the p53 alleles and the gene transcripts in human tumor cell lines by single-strand conformation polymorphism analysis
25. Database of p53 gene somatic mutations in human tumors and cell lines: Updated compilation and future prospects
26. Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent
27. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53
28. IARC database of p53 gene mutations in human tumors and cell lines: Updated compilation, revised formats and new visualization tools
29. Infrequent alteration of p53 pathway in metastatic renal cell carcinoma
30. The 72nd codon change of p53 in primary renal cell carcinoma was conformed as a polymorphism among Japanese
31. Normal p53 status and function despite the development of drug resistance in human breast cancer cells
32. p53 activity and chemosensitivity
33. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
34. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems
35. p53 and chemosensitivity
36. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
37. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4
38. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells
39. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis